Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB221 (Coprelotamab) + Capecitabine in HER2+ Advanced Breast Cancer
NCT04164615Phase 3Unknown
- Sponsor
- Genor Biopharma
- Start
- Nov 2016
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HER2-positive breast cancer comparing GB221 + Capecitabine with Placebo + Capecitabine (2 arms). Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
coprelotamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04164615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164615.